In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1787-1798

  Roomi, M W ^a   Kalinovsky, T ^a   Monterrey, J ^a   Rath, M ^a   Niedzwiecki, Aleksandra ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

Chondrosarcoma; Cytokines; Fibrosarcoma; Inducers; Inhibitors; Liposarcoma; Matrix metalloproteinases; Synovial sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXAMIDE; CYTOKINE; DACTINOMYCIN; DEXAMETHASONE; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHONDROSARCOMA; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSARCOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SYNOVIAL SARCOMA; TUMOR INVASION; ZYMOGRAPHY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOGENS; CATECHIN; CELL LINE, TUMOR; CHONDROSARCOMA; DACTINOMYCIN; DEXAMETHASONE; DOXYCYCLINE; FIBROSARCOMA; HUMANS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LIPOSARCOMA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; SARCOMA; SARCOMA, SYNOVIAL; TETRADECANOYLPHORBOL ACETATE; TRETINOIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891919714     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2113     Document Type: Article

References (42)

1. American Cancer Society: Adult soft tissue cancer. What are the key statistics about soft tissue sarcomas? http://www.cancer.org/cancer/sarcoma- adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-key- statistics. Last revised October 2, 2012. Accessed January 21, 2013.
2. American Cancer Society: Bone cancer. What are the key statistics about bone cancer? http://www.cancer.org/cancer/bonecancer/detailedguide/bone-cancer- key-statistics. Last revised November 29, 2012. Accessed January 21, 2013.
3. Papagelopoulos PJ, Galanis E, Frassica FJ, Sim FH, Larson DR and Wold LE: Primary fibrosarcoma of bone. Outcome after primary surgical treatment. Clin Orthop Relat Res 373: 88-103, 2000.
4. Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 12: 75-80, 2001.
5. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
6. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
7. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10: 383-392, 2001.
8. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
9. Sato T, Sakai T, Noguchi Y, Takta M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56, 2004.
10. Pyke C, Kristensen P, Ralfkiaer E, Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
11. Harvey P, Clark IM, Jourand MC, Warn RM and Edwards DR: Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147-1153, 2000.
12. Liu Z, Ivanoff A and Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91: 638-643, 2001.
13. Vincenti MP, White LA, Schroen DJ, Benbow U and Brinckerhoff CE: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription and mRNA stability. Crit Rev Eukaryot Gene Expr 6: 391-411, 1996.
14. Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 100: 463-471, 2002.
15. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteinase and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1994.
16. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322-2329, 1990.
17. Linder C, Linder S, Munck-Wickland E and Strander H: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18: 2063-2068, 1998.
18. Graeven U, Andre N, Achilles E, Zornig C and Schmeigel W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 125: 577-581, 1999.
19. Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84: 151-159, 2003.
20. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-543, 2010.
21. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 32: 243-248, 2010.
22. Roomi MW, Ivanov V, Kalinovsky T, Rath M and Niedzwiecki A: In vivo and in vitro antitumor effect of ascorbic acid, lysine, proline, arginine and green tea extract on human fibrosarcoma cells HT-1080. Med Oncol 23: 105-112, 2006.
23. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: In vitro and in vivo anti-tumor effect of a nutrient mixture containing ascorbic acid, lysine, proline and green tea extract on human synovial sarcoma cancer cells. JANA 9: 2, 2006.
24. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
25. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
26. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002.
27. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.
28. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71 (Suppl 6): 1698-1704, 2000.
29. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616 1998.
30. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
31. Hara Y: Green Tea: Health Benefits and Applications. Marcel Dekker, New York, Basel, 2001.
32. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
33. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.
34. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
35. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003.
36. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: The utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982.
37. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997.
38. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493, 1998.
39. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
40. Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995 (In Spanish).
41. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.
42. Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.